Defined Terms Section. Action 2.2(e) Affiliate 6.10(a) Agreement Preamble Bank 2.2(b) Burdensome Condition 2.2(d) Closing 1.2(a) Closing Date 1.2(a) Company Preamble Company SEC Reports 2.2(g) Company Subsidiary(ies) 2.2(b) Company’s Knowledge 6.10(f) Contemplated Transactions 2.2(c)(1) Exchange Act 2.2(d) FDIC 2.2(b) Federal Reserve 2.2(d)
Defined Terms Section. Exchange Fund 2.2(a) Excluded Party 8.13 Excluded Party Termination Fee End Date 8.13 Excluded Shares 2.1(a) FCPA 8.13 Financing 4.5(a) Financing Commitments 4.5(a) Financing Sources 8.13 Foreign Subsidiaries 5.1(b) GAAP 8.13 Governmental Antitrust Entity 8.13 Governmental Entity 8.13 Government Official 8.13 Guarantee 4.7 Guarantor(s) 4.7 Hazardous Substance 8.13 HSR Act 8.13 Indebtedness 8.13 Indemnified Parties 5.11(a) Initial Rollover Stockholder Recitals Intellectual Property 8.13 Intercompany Indebtedness 8.13 Intervening Event 8.13 IRS 8.13 IT Systems 8.13 Knowledge 8.13 Law or Laws 8.13 Lien 3.2(a) Malware 8.13 Marketing Period 8.13 Material Company Intellectual Property 8.13 Material Real Property Lease(s) 3.17(b) Merger Recitals Merger Sub Preamble Merger Transactions Recitals No-Shop Period Start Date 5.2(a) NYSE 8.13 OFAC 3.9(d) Order 3.7(b) Owned Intellectual Property 8.13 Owned Real Property 3.17(a) Parent Preamble Parent Benefit Plans 5.9(b) Parent Disclosure Letter Article IV Parent Required Governmental Approvals 4.3(a) Parent Termination Fee 8.13 Paying Agent 2.2(a) Per Share Merger Consideration 2.1(a) Permit 3.9(a) Permitted Encumbrances 8.13 Person 8.13 Proxy Statement 3.4(a) Record Holder of Shares 2.2(b) Redacted Fee Letter 4.5(a) Release 8.13 Relevant Person 3.9(c) Representatives 5.2(a) Required Financial Information 5.15(c)(v) Rollover Agreement Recitals Rollover Shares Recitals Rollover Stockholders Recitals RSU 2.3(c) Xxxxxxxx-Xxxxx Act 8.13 SEC 8.13 Securities Act 8.13 Share or Shares 2.1(a) Software 8.13 Solvent 8.13 Special Committee Recitals Stock Appreciation Right 2.3(b) Stockholders’ Meeting 5.4 Stock Plans 3.2(a) Stock Option 2.3(a) Subsidiary 8.13 Superior Proposal 8.13 Surviving Corporation 1.2 Takeover Statute 3.10 Tax or Taxes 8.13 Tax Return 8.13 Termination Date 7.2(a) Termination Fee 8.13 Trademarks 8.13 Trade Secrets 8.13 Transaction Litigation 5.17 Transactions Recitals UK Bribery Act 8.13 WARN 3.13 XXXXXX INTERNATIONAL, INC. THE UNDERSIGNED, being a natural person for the purpose of organizing a corporation under the Delaware General Corporation Law (the “DGCL”), hereby certifies that: FIRST: The name of the corporation is Xxxxxx International, Inc. (the “Corporation”).
Defined Terms Section. Signing Backlog 2.5(b) Software License Agreement 1.8(b)(ix) Specified IP 9.11 Subcontract Agreement 1.8(b)(vi) Sublease 1.8(b)(viii) Tax Contest 8.4(b)(i) Tax Returns Article X Taxes Article X Taxing Authority 8.4(a) Third Party Article X Trade Compliance Laws Article X Transaction Agreements Article X Transfer Taxes 8.1(c) Transition Services Agreement 1.8(b)(x) U.S. Acquired Assets 1.1 U.S. Assumption Agreement 1.4(a) U.S. Buyer Preamble U.S. Business Employees 9.3(a) U.S. Buyer Plans 9.3(a)(i)(A) U.S. New Buyer Employees 9.3(a)(i)(A) Unaudited Financial Statements 2.5(a) Vendors 2.19 WARN 9.3(h)(iv)
Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(a) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Partner 2.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iii) Joint Development Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed Xxxx 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 Remedial Action 5.9 Reversion Background IP 13.6(f) Reversion Collaboration IP 13.6(f) [***] [***] Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) VAT 8.10(c)
Defined Terms Section. Bankruptcy Code 6.6 Executive Officers 3.4 GCAR 4.4(a) GBM AGILE 4.4(a) IDL 4.5(d) Indemnified Party 10.3 Indemnifying Party 10.3 Joint Steering Committee or JSC 3.1 Xxxxx Indemnitees 10.2 Licensed Trademarks 6.7(a) Prior CDA 7.7 Product Marks 6.7(b) Recipient 7.3 Remedial Action 4.12 Review Period 5.5(f) Royalty Query 5.5(f) Royalty Report 5.5(e) Royalty Term 5.5(b) Securities Regulators 7.6(b) Share Subscription Agreement 5.2 Simcere Indemnitees 10.1 Territory Infringement 6.3
Defined Terms Section. 409A Authorities Section 3.11(e) Adjusted Shareholders’ Equity Section 10.01(f) Agreement Preamble AJCA Section 3.11(e) ALL Section 3.28 Articles of Merger Section 1.02 Bank Section 3.01 Certificate Section 1.06(a) Change in Board Recommendation Section 6.03(b) Claim Section 7.02(a) Closing Section 2.01 Closing Balance Sheet Date Section 6.06 Closing Date Section 2.01 Closing Financial Statements Section 6.06
Defined Terms Section. Insurance Amount Section 7.02(c) Intellectual Property Section 3.17(a) IRS Section 3.11(b) Leased Properties Section 3.20(b) Liens Section 3.04 Loans Section 3.23(a) Materially Burdensome Regulatory Condition Section 5.04(a) Merger Recitals Merger Consideration Section 1.06(a) Merger Sub Recitals Nonqualified Deferred Compensation Plan Section 3.11(e) OCC Section 3.08(a) Option Consideration Section 1.08 Option Spread Section 1.08 Owned Properties Section 3.20(b) Parent Preamble Parent Benefit Plans Section 7.01(a) Parent Disclosure Schedule Article IV Parent Expenses Section 11.03
Defined Terms Section. Xxxx Trademarks Section 9.6(b) Manufacture Technology Transfer Section 6.2 Manufacturing Technology Transfer Materials Section 6.2 Manufacturing Technology Transfer Plan Section 6.2 Other Product Section 2.8(a) Other Product Transaction Section 2.8(a) Parties Preamble Party Preamble Pharmacovigilance Agreement Section 5.6 Prior CDA Section 10.6 Product Infringement Section 9.3(b) Product Marks Section 9.6(a) Region Section 1.62 Remedial Action Section 5.9 ROFN Section 2.8(a) ROFN Exercise Period Section 2.8(b) ROFN Expiry Date Section 2.8(c) ROFN Negotiation Period Section 2.8(a) Royalty Term Section 8.5(b) [***] [***] [***] [***] SEC Section 10.5(b) Sole Inventions Section 9.1(a)(i) Target Entity Section 1.3 Taxes Section 8.10 Term Section 13.1(a)
Defined Terms Section. Company Related Party 8.13 Company Required Governmental Approvals 3.4(a) Company Requisite Vote 3.3(a) Company SEC Filing 5.15(c)(vi) Company SEC Reports 3.5(a) Confidentiality Agreements 8.9 Constituent Corporation Preamble Contract 8.13
Defined Terms Section. Director Section 4.01 Eligibility Criteria Section 3.01(b) Executive Officer Section 5.01(b) FDX API FS-XXXX XXXX Director Director Preamble Preamble Section 4.02(a) Section 4.02 Ineligible Member Section 3.05 Liquidators Section 9.01 Losses Section 7.01(a) Membership Dues Section 3.03 Membership Termination Event Section 3.05 Officers Section 5.01(b) Other Activity Section 6.02(b) President Section 5.01(a) Secretary Section 4.15 Surviving Entity Definition – Change of Control Transfer Working Groups ARTICLE 2 Section 2.11 Section 4.17
